INITIO Medical Receives ICPO Accreditation as First Theranostics Clinical Center in North America
INITIO Medical Achieves Landmark Accreditation
In a significant advancement for healthcare in North America, INITIO Medical has been recognized as the first Theranostics Clinical Center of Excellence by the International Centers for Precision Oncology Foundation (ICPO). This prestigious accreditation places INITIO Medical at the forefront of precision oncology, making it a pioneer in the field within Canada and North America.
A New Era for Theranostics
The announcement was made on October 16, 2025, and it emphasizes INITIO’s steadfast commitment to advancing the field of Theranostics—an innovative cancer therapy that combines diagnostics and therapeutics. Dr. Odile Jaume, CEO of the ICPO Foundation, expressed her excitement about this milestone, noting that this achievement follows strict international guidelines set forth by reputable organizations such as SNMMI and EANM.
Dr. Jaume stated, "We are proud to acknowledge INITIO Medical's leadership in this area and to welcome them to our ICPO Center Network, helping to further our mission to expand patient access to groundbreaking cancer therapies."
Formal Recognition
The official recognition was presented during the ICPO Reception Center Certification Ceremony held in Barcelona on October 4, 2025, prior to the annual meeting of the EANM. Dr. Philip Cohen and Mina Bechai of INITIO Medical accepted this honor, symbolizing their hard work and dedication to improving patient care through precision oncology.
Mina Bechai, Founder, and CEO of INITIO Medical commented on the significance of this recognition: "We are incredibly honored to be the first center in North America to receive this accreditation. Our team is dedicated to enhancing patient outcomes through advanced therapeutic solutions, and we eagerly look forward to working closely with the ICPO Foundation."
Strengthening Collaboration
The partnership between INITIO Medical and the ICPO Foundation aims to prioritize education in this field through the ICPO Academy for Theranostics. This collaboration will enhance training resources and ensure that healthcare professionals are equipped with the latest information and skills essential for practicing Theranostics effectively, ultimately benefiting patients in Canada and beyond.
Dr. Francois Lamoureux, President of the Canadian Association of Nuclear Medicine (CANM), praised INITIO’s accomplishment, asserting that it reflects Canada’s growing leadership in nuclear medicine. He stated, "This recognition is not only a proud moment for us but also a sign of increasing expertise in our nation’s capability to deliver top-tier nuclear medicine services."
About INITIO Medical Group
INITIO Medical Group is dedicated to revolutionizing cancer care with innovative solutions in radiopharmaceuticals. The group focuses on bridging gaps in healthcare by fostering strategic partnerships and enhancing access to therapeutic technologies. Their mission is to elevate the standards of cancer treatment in Canada while improving patient outcomes across the board. For more information on their groundbreaking efforts, visit their website at www.initiomedical.ca.
About the ICPO Foundation
Founded in 2019, the ICPO Foundation is a nonprofit organization dedicated to enhancing patient access to Radiomolecular Precision Oncology. With aims to reduce side effects while improving treatment efficacy, the foundation provides robust education and builds a network of certified ICPO Centers worldwide. Its mission is to foster innovative cancer care globally. Visit their website at www.icpo.foundation to learn more.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.